Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hua MedicineHUMDF 44 EV-to-EBITDA is 1.05 as of Jul. 31, 2026. GuruFocus rates HUMDF with a GF Score™ of 44/100 and a GF Value™ of $1.18 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 747 Drug Manufacturers companies, Hua Medicine ranks better than 95.72% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hua Medicine's enterprise value is $167.92 Mil.
Hua Medicine's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $159.58 Mil. Therefore, Hua Medicine's EV-to-EBITDA for today is 1.05.
The historical rank and industry rank for Hua Medicine's EV-to-EBITDA or its related term are showing as below:
HUMDF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -23.11 Med: -5.34 Max: 2.29
Current: 1.05
During the past 10 years, the highest EV-to-EBITDA of Hua Medicine was 2.29. The lowest was -23.11. And the median was -5.34.
HUMDF's EV-to-EBITDA is ranked better than 95.72% of 747
companies
in the Drug Manufacturers industry
Industry Median: 12.88
vs HUMDF: 1.05
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Hua Medicine (OTCPK:HUMDF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hua Medicine's PE Ratio (TTM) for today is calculated as:
Hua Medicine's share price for today is $0.31435.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hua Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.153.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Hua Medicine's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hua Medicine's EV-to-EBITDA falls into.
Hua Medicine's current Enterprise Value is $167.92 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hua Medicine's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $159.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hua Medicine (HUMDF) has a EV-to-EBITDA of 1.05 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hua Medicine. According to the industry distribution chart, Hua Medicine ranks #32 out of 747 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Hua Medicine's EV-to-EBITDA too high?
Hua Medicine's current EV-to-EBITDA is 1.05. The Drug Manufacturers industry median EV-to-EBITDA is 12.88. Hua Medicine's value of 1.05 is 91.8% below this industry median. Based on the distribution chart, Hua Medicine ranks #32 out of 747 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hua Medicine has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hua Medicine ranks #32 out of 747 companies for EV-to-EBITDA. This places Hua Medicine in the top 4% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.88. Hua Medicine's value of 1.05 is 91.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.88, based on 747 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hua Medicine's current EV-to-EBITDA of 1.05 is 91.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Hua Medicine. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hua Medicine's current EV-to-EBITDA is 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.18, compared to a current price of $0.31 — trading 73.4% below its estimated fair value. The current EV-to-EBITDA is 1.05 and 91.8% below the Drug Manufacturers industry median of 12.88. Hua Medicine's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current EV-to-EBITDA is 1.05 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hua Medicine (HUMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued.
The current stock price of $0.31 is trading 73.4% below its estimated GF Value™ of $1.18.
GuruFocus considers Hua Medicine to be Possible Value Trap.
Key valuation signals for HUMDF:
EV-to-EBITDA: 1.05
GF Value™: $1.18 vs. price of $0.31 (73.4% below fair value)
Industry Position: 91.8% below the Drug Manufacturers median (#32 of 747)
No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
44GF Score
Get the complete analysis for HUMDF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HUMDF has been successfully added to your 
